- Company
- Takeda Korea appoints Kwang-gyu Park as new General Manager
- by Whang, byung-woo Mar 19, 2025 06:02am
- Takeda Pharmaceuticals Korea announced on the 18th that it has appointed Kwang-kyu Park as its new General Manager as of March 17, 2025. Park is a pharmaceutical industry expert with more than 20 years of experience in the industry and strong expertise and leadership in Specialty Care and Oncology (hematologic malignancies and immunotherap
- Company
- Ilaris can be prescribed in 7 hospitals in Korea
- by Eo, Yun-Ho Mar 19, 2025 06:01am
- The ultra-rare disease treatment 'Ilaris' may now be prescribed in more hospitals in Korea. According to industry sources, Novartis Korea's hereditary recurrent fever syndrome drug Ilaris (canakinumab) has passed the drug committees (DCs) of tertiary hospitals such as Seoul National University Hospital, Seoul St. Mary's Hospital, and Sinc
- Company
- Vadanem for renal anemia makes its 'third attempt at reimb'
- by Nho, Byung Chul Mar 18, 2025 05:57am
- Attention has been drawn to the oral renal anemia drug Vadanem as the company completed meeting procedural requirements and attempts again to obtain reimbursement listing. According to industry sources, Mitsubishi Tanabe Pharma recently submitted Vadanem's drug pricing application to the Health Insurance Review and Assessment Service (H
- Company
- Alteogen signs 2 licenses out agreements with AZ subsidiary
- by Cha, Jihyun Mar 18, 2025 05:56am
- Alteogen has signed two licensing-out agreements with AstraZeneca’s subsidiaries. According to the Financial Supervisory Service on the 17th, Alteogen has signed 2 exclusive license agreements with MedImmune, a subsidiary of AstraZeneca's bio R&D, for its subcutaneous (SC) formulation modification platform 'ALT-B4' based on recombinant h
- Company
- Can the myelofibrosis drug Ojjara pass CDDC review in KOR?
- by Eo, Yun-Ho Mar 18, 2025 05:56am
- Industry attention is rising on whether GSK’s new drug for myelofibrosis, Ojjara, will be able to make progress in its reimbursement journey and be listed in Korea. According to industry sources, GSK's myelofibrosis treatment Ojjara (momelotinib) will be presented for review to the Health Insurance Review and Assessment Service's Cancer
- Company
- Pfizer distributed KRW 160 billion dividend over 2 years
- by Chon, Seung-Hyun Mar 18, 2025 05:56am
- Pfizer Korea has decided on a large-scale dividend payout for the second consecutive year. While the company maintained an annual dividend policy of KRW 12.48 million, it has distributed KRW 160 billion to its parent company over the past two years. Large-scale profits during the COVID-19 pandemic enabled this high dividend. According to the
- Company
- Sanofi 'Dupixent' adds COPD indication
- by Whang, byung-woo Mar 17, 2025 06:00am
- 'Dupixent,' dominating the market for atopic dermatitis·asthma drugs, has expanded treatment areas to chronic obstructive pulmonary disease (COPD), thus gaining attention. Since Dupixent was approved for expanded reimbursement last year, the latest news on COPD indication will likely improve its prescription competitiveness. According
- Company
- K-Bios busy developing new CAR-NK cell therapies
- by Son, Hyung Min Mar 17, 2025 06:00am
- The domestic pharmaceutical industry is initiating clinical trials for cell therapies and confirming new possibilities. GC Cell, Isu Abxis, Vaxcell Bio Therapeutics, GI Cell, and HK Inno.N are developing CAR-NK (chimeric antigen receptor) cell therapies. CAR-NK, which is derived from allogeneic cells, has the advantage of being able to compen
- Company
- BESREMi lands in Big 5 Hospitals in Korea
- by Eo, Yun-Ho Mar 17, 2025 05:59am
- BESREMi, a new drug for polycythemia vera, has been approved for prescription at tertiary hospitals in Korea. According to the industry sources, PharmaEssentia Korea's BESREMi (ropeginterferon&160;alfa-2b, a treatment for polycythemia vera, has recently passed the Drug Committees (DCs) of the Big 5 medical institutions in Korea, includin
- Company
- Radioligand 'Pluvicto' available at tertiary gen hospitals
- by Eo, Yun-Ho Mar 17, 2025 05:59am
- 'Pluvicto,' a new drug for prostate cancer, is now available for prescription at tertiary general hospitals. According to industry sources, Novartis Korea's targeted radioligand therapy, Pluvicto (Lutetium vipivotide tetraxetan), has passed the drug committees (DC) of the 'Big 5' hospitals, including Samsung Medical Center, Asan Medical C
